NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria NEW YORK, Dec. 14, 2020 /PRNewswire/ -- BrainStorm Cell ...
NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data ...
A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time NEW YORK, April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. There’s bi-partisan support in North ...
NEW YORK, Oct. 28, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of ...
The webinar will take place on July 8, 2020 at 8:15 AM ET. The presentation will be followed by a question-and-answer session with Professors Scheltens and Dubois and with BrainStorm management.
LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma. Background: Better knowledge on the evolving epidemiology and biology of CNS metastases are key elements for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results